Group 1 - The core viewpoint is that Guotai Junan Securities maintains an "overweight" rating for Weigao Co., Ltd. (01066) and sets a target price of HKD 7.84, as Weigao Blood Products plans to acquire 100% of Weigao Purui's shares, positioning itself as the controlling shareholder and flagship platform for medical devices within the group [2][3] - The acquisition is expected to be completed in the second half of 2026, with Weigao Blood Products currently holding 23.53% of Weigao Co. and 94.07% of Weigao Purui prior to the transaction [3] - The assessed value of Weigao Purui's 100% equity is estimated at CNY 8.511 billion, with a share issuance price of CNY 31.29 per share, leading to the issuance of 272 million shares, which will constitute 39.43% of the total post-issuance share capital [3] Group 2 - The upstream biopharmaceutical market is expanding rapidly, with a projected market size of CNY 21.2 billion in 2024 and a compound annual growth rate (CAGR) of 11.5% expected from 2024 to 2030, indicating significant opportunities for domestic substitution [4] - Weigao Blood Products has established a product line for upstream biopharmaceutical filtration, while Weigao Purui possesses extensive customer resources in the biopharmaceutical sector, suggesting potential synergies post-acquisition [4] - Following the transaction, Weigao Co. will hold 52.10% of Weigao Blood Products, becoming its controlling shareholder and further clarifying its position as the flagship platform for medical devices under the Weigao brand [5]

智通财经APP获悉，国泰海通证券发布研报称，维持威高股份(01066)"增持"评级，给予目标价7.84港 元，威高血净拟发行股份收购威高普瑞全部股权，通过此次整合，威高股份将成为威高血净的控股股 东，进一步明确其作为集团旗下医疗器械旗舰平台的定位。双方有望在生物制药上游领域形成协同，把 握国产替代机遇，拓展增长空间，交易预计在2026年中后期完成。 根据公司投资者演示材料，2024下半年以来随着创新药发展迅速、BD交易火热，生物制药上游领域需 求快速修复，2024年中国市场规模212亿元，2024-2030E复合增速有望达到11.5%。竞争格局来看，国产 化率总体偏低，国产替代机会大。目前威高血净已建立起了生物制药上游过滤产品线，而威高普瑞在生 物制药拥有广泛的客户资源，交易后双方有望进一步发挥协同作用，充分把握生物制药上游市场机遇， 拓展未来增长空间。 公司医疗器械旗舰平台定位进一步明确 交易后，公司将持有威高血净52.10%股权，成为其控股股东并合并财务报表。本次交易将进一步整合 并优化威高品牌下的核心医疗资产，公司将成为威高集团旗下医疗器械的旗舰型平台。 风险提示 新业务拓展不及预期，业绩承诺未能完成的 ...

威高股份(01066)发布公告，于2026年1月9日该公司斥资234.26万港元回购44万股，回购价格为每股5.29- 5.34港元。 ...

格隆汇1月9日丨威高股份(01066.HK)发布公告，2026年1月9日耗资234.26万港元回购44万股，回购价格 每股5.29-5.34港元。 ...

智通财经APP讯，威高股份(01066)发布公告，于2026年1月9日该公司斥资234.26万港元回购44万股，回 购价格为每股5.29-5.34港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2026年1月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - Insilico Medicine announced a collaboration with Servier valued at $888 million focused on the discovery and development of innovative anti-cancer therapies [1] - Insilico will receive up to $32 million in upfront and milestone payments, leveraging its AI-driven drug development platform [1] - Servier will lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2 - Weigao Blood Products announced a major asset restructuring involving the acquisition of 100% equity in Weigao Purui for approximately $8.511 billion [2] - Post-transaction, Weigao Purui will become a wholly-owned subsidiary, expanding the company's business into pharmaceutical packaging [2] - Weigao's shareholding in Weigao Blood Products will increase to 84.36%, maintaining absolute control [2] Group 3 - Earendil Labs (HuaShen ZhiYao) entered a strategic partnership with Sanofi worth up to $2.56 billion for the development of bispecific candidates targeting autoimmune and inflammatory diseases [3] - Earendil Labs will receive up to $160 million in upfront and milestone payments linked to early project outcomes [3] - The agreement includes tiered royalties based on net sales [3] Group 4 - WuXi AppTec announced that its controlling shareholders have reduced their stake by 2%, totaling 59.68 million shares [4] - The reduction was completed as per the previously disclosed plan, with the controlling shareholders holding 18.211% of the total shares before the reduction [4] Group 5 - Nanhua Biological announced plans for a significant asset restructuring to acquire 51% of Huize Pharmaceutical for cash [5] - The transaction is expected to constitute a major asset restructuring without involving share issuance or control changes [5] - Due diligence and negotiations are ongoing, with no formal agreement signed yet [5] Group 6 - Kangchen Pharmaceutical projected a net profit of between 145 million to 175 million yuan for 2025, representing a year-on-year increase of 243% to 315% [6] - The expected net profit excluding non-recurring gains is projected to be between 140 million to 170 million yuan, reflecting a significant increase from the previous year [6] Group 7 - Yilian Biotech signed a new exclusive licensing agreement with Roche for the YL201 project, with an upfront payment of $570 million [7] - The agreement allows Roche exclusive rights to develop and commercialize the YL201 project globally, excluding mainland China and certain regions [7] - This partnership builds on a successful collaboration on the YL211 project, aiming to accelerate the development of YL201 [7]

Company Dynamics - Weigao Co. announced the progress of the share swap transaction with Weigao Blood Products on January 5, 2026, confirming the final valuation of Weigao Purui at RMB 8.511 billion, corresponding to a static P/E of 14.66x for 2024 [1] - The share swap will result in Weigao Co. controlling 51.35% of Weigao Blood Products, increasing its stake from 23.53% to 51.35%, and Weigao Blood Products will hold 100% of Weigao Purui [1] - The transaction is expected to be voted on at a shareholders' meeting in February 2026, with completion anticipated in 2-3Q 2026 [1] Performance Commitment - Weigao Co. has set a reasonable and cautious performance commitment for Weigao Purui, targeting net profits of RMB 639 million, RMB 720 million, and RMB 784 million for the years 2026-2028, reflecting a compound annual growth rate (CAGR) of 10.7% [2] - If the transaction is delayed until 2027, the profit commitments for 2027-2029 will be RMB 720 million, RMB 784 million, and RMB 845 million, with a CAGR of 8.3% [2] Industry Outlook - Weigao Blood Products focuses on consumables and equipment for blood dialysis and peritoneal dialysis, while Weigao Purui specializes in pre-filled delivery systems and automatic safety delivery systems, aligning with the customer base of the biopharmaceutical upstream business [2] - The upstream biopharmaceutical market in China is projected to reach RMB 21.2 billion in 2024, with expectations to grow to RMB 40.6 billion by 2030, reflecting a CAGR of 11.5% and significant potential for domestic substitution due to low localization rates [2] Profit Forecast and Valuation - Considering the need for time to expand upstream and slightly higher procurement pressure than expected for the first half of 2025, the net profit forecasts for 2025 and 2026 have been revised down by 7% to RMB 1.989 billion and RMB 2.183 billion, respectively, with a new forecast of RMB 2.348 billion for 2027 [2] - The current stock price corresponds to P/E ratios of 9.9x for 2026 and 8.9x for 2027, with a target price maintained at HKD 6.40, implying a P/E of 12.1x for 2026 and 11.3x for 2027, indicating a potential upside of 22.4% [2]

证券时报·数据宝统计，威高股份在港交所公告显示，1月8日以每股5.200港元至5.260港元的价格回购 99.48万股，回购金额达519.96万港元。该股当日收盘价5.240港元，下跌1.50%，全天成交额5857.12万 港元。 威高股份回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2026.01.08 | 99.48 | 5.260 | 5.200 | 519.96 | | 2026.01.07 | 108.00 | 5.350 | 5.260 | 573.16 | | 2026.01.06 | 159.48 | 5.230 | 5.010 | 822.33 | （文章来源：证券时报网） 自1月6日以来公司已连续3日进行回购，合计回购366.96万股，累计回购金额1915.45万港元。 其间该股 累计下跌1.13%。（数据宝） ...

智通财经APP讯，威高股份(01066)发布公告，于2026年1月8日，该公司斥资519.96万港元回购99.48万股 股份，每股回购价格为5.2-5.26港元。 ...